Iressa 250 mg Alternative – Geficent (Gefitinib) 250 mg Tablet | Incepta Pharmaceuticals
Geficent 250 mg (Gefitinib) Tablet is listed in the supplied Lucent price catalogue attributed to Incepta Pharmaceuticals Ltd. Reference brand: Iressa (AstraZeneca).
Pack: 10 tablets. Prescription medicine. Verify the exact manufacturer label and regulatory status; reference-brand comparison does not establish interchangeability.
Product Overview
Geficent 250 mg is listed in the supplied Lucent product catalogue. Its proposed active ingredient is Gefitinib, in tablet form. The manufacturer’s product labeling should be consulted for the final specification.
Geficent vs Iressa – Reference Brand Comparison
Iressa is a recognized reference brand associated with AstraZeneca. Geficent is listed on the supplied Lucent products price sheet, attributed by the customer to Incepta Pharmaceuticals Ltd. Matching an active ingredient does not demonstrate bioequivalence, regulatory approval or permission to substitute.
Composition and Product Details
- Listed brand: Geficent
- Generic: Gefitinib
- Strength: 250 mg
- Dosage form: Tablet
- Catalogue pack: 10 tablets
- Attributed manufacturer: Incepta Pharmaceuticals Ltd., Bangladesh
Therapeutic Uses and Indications
Gefitinib is used in EGFR-mutated non-small cell lung cancer. These are generic-medicine contexts, not independently confirmed approvals for this particular branded presentation. Exact eligible conditions, biomarkers and combination therapies must be confirmed from the local authorized label.
Mechanism of Action
Gefitinib inhibits EGFR signaling. Individual treatment response depends on the disease, formulation, dosing and patient factors.
Dosage and Administration
The stated 250 mg refers to the strength of the supplied product, not a recommended daily or treatment dose. Administration schedules, preparation, food instructions and monitoring depend on the approved indication and formulation. Use only the dose and schedule prescribed by a qualified clinician. Never change strength or substitute a brand without medical advice.
Contraindications
Contraindications can include hypersensitivity and other medicine-specific conditions. Review the current prescribing information for all absolute restrictions, including relevant pregnancy-related contraindications.
Warnings and Precautions
Potential serious risks and monitoring requirements vary by medicine. Discuss infections, cardiovascular disease, liver and kidney function, other medications and pregnancy plans with the specialist. The official product leaflet determines the required safety monitoring.
Possible Side Effects
Adverse reactions may involve gastrointestinal symptoms, fatigue, laboratory abnormalities, infections or organ-specific toxicity, depending on the active ingredient. The full medicine-specific adverse effect profile, frequency and emergency warning signs must be reviewed in the authorized prescribing information.
Drug Interactions
Prescription drugs, nonprescription medicines, herbal products and some foods may interact with Gefitinib. A pharmacist or specialist should review all current medicines before treatment.
Pregnancy and Breastfeeding
Some treatments can cause fetal harm or require interruption of breastfeeding. Consult the product-specific label and treating specialist for pregnancy testing, contraception and breastfeeding guidance.
Storage and Handling
Follow the temperature, light protection, cold-chain and handling requirements printed on the actual pack. Do not assume storage conditions from another brand or formulation.
Why Is Geficent Listed as an Alternative to Iressa?
The comparison is provided for product discovery by active ingredient and reference brand. It does not establish pharmaceutical or therapeutic equivalence, biosimilarity, interchangeability or authorization in any country.
Manufacturer Information
Listed manufacturer: Incepta Pharmaceuticals Ltd., Bangladesh
Reference brand: Iressa
Reference company: AstraZeneca
Generic: Gefitinib
Strength: 250 mg
Pack: 10 tablets
Frequently Asked Questions
What does Geficent contain?
Gefitinib 250 mg, subject to confirmation against the official brand-specific label.
Is Geficent the same as Iressa?
No automatic equivalence or interchangeability can be inferred from the generic ingredient alone.
Can I use another strength instead?
Only when an authorized clinician specifically directs it.
Is a prescription required?
Yes. Appropriate prescription and specialist supervision are required.
Important Medical Disclaimer
Educational product identification only. Clinical information and product availability require verification against official labeling and destination-country regulatory requirements. No purchase or treatment decision should be based on this page alone.
| Generic Name | Gefitinib |
|---|---|
| Strength | 250 mg |
| Manufacturer | Incepta Pharmaceuticals Ltd. |
| Pack Size | 10 tablets |
Related products
Alunbrig 180 mg Alternative – Brigacent (Brigatinib) 180 mg Tablet | Incepta Pharmaceuticals
Brigacent 180 mg (Brigatinib) Tablet is listed in the supplied Lucent price catalogue attributed to Incepta Pharmaceuticals Ltd. Reference brand: Alunbrig (Takeda).
Pack: 7 tablets. Prescription medicine. Verify the exact manufacturer label and regulatory status; reference-brand comparison does not establish interchangeability.
Alunbrig 90 mg Alternative – Brigacent (Brigatinib) 90 mg Tablet | Incepta Pharmaceuticals
Brigacent 90 mg (Brigatinib) Tablet is listed in the supplied Lucent price catalogue attributed to Incepta Pharmaceuticals Ltd. Reference brand: Alunbrig (Takeda).
Pack: 7 tablets. Prescription medicine. Verify the exact manufacturer label and regulatory status; reference-brand comparison does not establish interchangeability.
Lumakras / Lumykras 120 mg Alternative – Sotoxen (Sotorasib) 120 mg Tablet | Everest Pharmaceuticals
Sotoxen 120 mg (Sotorasib) by Everest Pharmaceuticals Ltd. is listed as an alternative-brand option for customers researching Lumakras / Lumykras (Amgen). It belongs to the KRAS G12C inhibitor class and is used in selected KRAS G12C-mutated non-small cell lung cancer.
Active ingredient: Sotorasib
Strength: 120 mg
Form: Tablet
Manufacturer: Everest Pharmaceuticals Ltd., Bangladesh
Prescription required. Shared active ingredients do not establish bioequivalence or automatic interchangeability.
Tarceva 100 mg Alternative – Erlocent (Erlotinib) 100 mg Tablet | Incepta Pharmaceuticals
Erlocent 100 mg (Erlotinib) Tablet is listed in the supplied Lucent price catalogue attributed to Incepta Pharmaceuticals Ltd. Reference brand: Tarceva (Roche / Genentech).
Pack: 10 tablets. Prescription medicine. Verify the exact manufacturer label and regulatory status; reference-brand comparison does not establish interchangeability.
Tarceva 150 mg Alternative – Erlocent (Erlotinib) 150 mg Tablet | Incepta Pharmaceuticals
Erlocent 150 mg (Erlotinib) Tablet is listed in the supplied Lucent price catalogue attributed to Incepta Pharmaceuticals Ltd. Reference brand: Tarceva (Roche / Genentech).
Pack: 10 tablets. Prescription medicine. Verify the exact manufacturer label and regulatory status; reference-brand comparison does not establish interchangeability.
Vizimpro 45 mg Alternative – Dacocent (Dacomitinib) 45 mg Tablet | Incepta Pharmaceuticals
Xalkori 250 mg Alternative – Alkixen (Crizotinib) 250 mg Capsule | Everest Pharmaceuticals
Alkixen 250 mg (Crizotinib) by Everest Pharmaceuticals Ltd. is listed as an alternative-brand option for customers researching Xalkori (Pfizer). It belongs to the ALK/ROS1 kinase inhibitor class and is used in selected ALK-positive or ROS1-positive non-small cell lung cancer.
Active ingredient: Crizotinib
Strength: 250 mg
Form: Capsule
Manufacturer: Everest Pharmaceuticals Ltd., Bangladesh
Prescription required. Shared active ingredients do not establish bioequivalence or automatic interchangeability.

Reviews
There are no reviews yet.